Videos

An expert reviews the ongoing ARIEL4 phase III trial and explains what the future of ovarian cancer treatment looks like.

Lyndsay Willmott, MD, explains the tolerability of PARP inhibitors for ovarian cancer and how to discuss dose reductions with patients.

A key opinion leader shares data from a phase III, ARIEL3, clinical trial on rucaparib maintenance treatment for ovarian cancer.

Dr. Lyndsay Willmott discusses the front-line therapy options for ovarian cancer and the factors considered in choosing maintenance therapies.

The rationale for studying plinabulin, a first-in-class selective immunomodulating microtubule binding agent, for the prevention of chemotherapy-induced neutropenia.

An oncologist explains the importance of molecular testing in ovarian cancer and the implications of testing on treatment selection.

Strategies for prophylaxis against chemotherapy-induced neutropenia in the setting of metastatic disease.

Lyndsay Willmott, MD, presents the case of a 57-year-old woman with ovarian cancer.

Neeraj Agarwal, MD, discusses how the prostate-specific antigen responses correlate with survival outcomes in 2 phase 3 trials of apalutamide in patients with advanced prostate cancer.

Dr Mazyar Shadman and Dr Brian T. Hill focus on CD19 being targeted in monoclonal antibody therapy options for relapsed/refractory diffuse large B-cell lymphoma, specifically tafasitamab.

Drs Shadman and Hill discuss using CD19 as a targeted therapy option in CAR T cell therapy for relapsed/refractory diffuse large B-cell lymphoma.

An oncologist discusses the future of myelodysplastic syndrome, including upcoming studies and potential treatments.

Dr. Naval Daver provides insight on the emerging first-line treatment options for high-risk myelodysplastic syndrome and breaks down clinical trial data.

An expert details the treatment options for high-risk myelodysplastic syndrome.

Naval Daver, MD, illustrates the goals of treatment and treatment options for low-risk myelodysplastic syndrome.

A key opinion leader describes how myelodysplastic syndrome is diagnosed, the typical presenting symptoms, and the methods of risk assessment.

Naval Daver, MD, explains myelodysplastic syndrome, including risk factors and potential complications.

Jesús García-Foncillas, MD, PhD, discusses the rationale behind comparing the efficacy of larotrectinib and entrectinib head-to-head in patients with metastatic solid tumors with neurotrophic gene fusions.

Chung-Han Lee, MD, PhD, discusses the phase 2 KEYNOTE-B61 trial of pembrolizumab plus lenvatinib in patients with non–clear cell renal cell carcinoma.

Theodore W. Laetsch, MD, an attending physician at the Cancer Center at Children’s Hospital of Philadelphia, discusses the efficacy of larotrectinib in patients with TRK-fusion cancers.

Michael D. Chuong, MD, a radiation oncologist and medical director of Proton Therapy at Miami Cancer Institute, Baptist Health South Florida, discusses the benefits of MRI-guided radiation therapy in pancreatic cancer.

Limitations of current therapies available for the prevention and management of chemotherapy-induced neutropenia.

Current mitigation and management strategies for chemotherapy-induced neutropenia.

John Diaz, MD, discusses the current results of the phase 1 trial of STRO-002, a novel FRα-targeting antibody-drug conjugate, in patients with ovarian cancer.

The experts delve further into treatment methods for relapsed/refractory diffuse large B-cell lymphoma, particular for transplant-eligible and -ineligible patients.

Mazyar Shadman, MD, MPH, and Brian T. Hill, MD, PhD, explain the intricacies of the diffuse large B-cell lymphoma treatment landscape.

Corey S. Cutler, MD, MPH, FRCPC, discusses the trial of belumosudil in patients with chronic graft-vs-host disease.

John Marshall, MD, speaks on regorafenib sequencing and relays his thoughts on the future of treatment for metastatic colorectal cancer.

Dr Marshall discusses the impact regorafenib has had in the treatment of metastatic colorectal cancer and describes data from the CORRECT and ReDOS clinical trials.

A gastrointestinal cancers expert describes monitoring strategies for progression of metastatic colorectal cancer.